Dayvigo Slow Titration for Sensitivity: How to Titrate Lemborexant Safely

What Is Lemborexant and Why Does Titration Matter?

Lemborexant blocks both orexin OX1 and OX2 receptors, reducing the wake-promoting signal that keeps the arousal system active at night. Unlike benzodiazepines, it does not broadly suppress the central nervous system. Still, residual sedation the morning after is the most common adverse event reported in clinical trials, affecting roughly 10 to 20 percent of patients at the 10 mg dose, which is why starting at the lower 5 mg strength and titrating slowly matters clinically.

Mechanism Relevant to Sensitivity

The dual orexin receptor antagonist (DORA) class includes suvorexant (Belsomra) and lemborexant. Lemborexant has a higher binding affinity for OX2R than suvorexant does, and its active metabolite M10 contributes meaningfully to sedation duration. Patients with low body weight, advanced age (65 or older), hepatic impairment, or who are taking CYP3A4 inhibitors all face higher plasma exposures and are therefore more likely to experience carry-over sedation. The FDA label for lemborexant specifies that the recommended starting dose for most adults is 5 mg and that the dose should not exceed 5 mg in patients taking moderate CYP3A4 inhibitors. [1]

Who Is Considered "Sensitive"?

Several patient groups warrant a conservative start:

• Adults aged 65 or older, in whom the FDA label advises caution given pharmacokinetic differences [1]
• Patients with mild-to-moderate hepatic impairment (Child-Pugh A or B), where lemborexant AUC increases by up to 45 percent [1]
• Patients taking moderate CYP3A4 inhibitors such as fluconazole, diltiazem, or erythromycin
• Patients with a history of excessive daytime sleepiness or obstructive sleep apnea
• Patients who previously experienced somnolence or complex sleep behaviors on other sedative-hypnotics

FDA-Approved Dosing Schedule

The FDA-approved label defines a narrow two-dose range. There is no approved dose below 5 mg, and no dose above 10 mg. [1]

Standard Adult Schedule

| Step | Dose | When to advance | |------|------|-----------------| | Start | 5 mg at bedtime | After 2 to 4 weeks if tolerated and inadequate response | | Escalation | 10 mg at bedtime | Maintain if response is adequate; reduce back to 5 mg if next-morning somnolence occurs |

The label states: "The recommended dose of DAYVIGO is 5 mg, taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. If the 5 mg dose is well tolerated but not optimally effective, the dose can be increased to 10 mg." [1]

When the Maximum Dose Is 5 mg

The FDA label restricts the ceiling to 5 mg in two situations: concurrent use of a moderate CYP3A4 inhibitor, and patients with moderate hepatic impairment. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole) contraindicate lemborexant entirely because they roughly double plasma exposure. [1]

Evidence From SUNRISE-1 on Dose-Dependent Effects

SUNRISE-1 was a randomized, double-blind, placebo-controlled trial (N=291) published in JAMA Network Open in 2019 that compared lemborexant 5 mg, lemborexant 10 mg, and zolpidem extended-release 6.25 mg over 30 nights in adults aged 55 or older with insomnia disorder. [2]

Sleep Latency and Maintenance

Both lemborexant doses outperformed placebo on polysomnographic sleep-onset latency (sSOL). At month 1, subjective sleep-onset latency improved by 18.7 minutes with 10 mg and 14.9 minutes with 5 mg versus placebo. Wake after sleep onset (WASO) in the second half of the night, a metric particularly relevant to sleep-maintenance insomnia, was also significantly reduced at both doses compared with zolpidem ER (P<0.05). [2]

Next-Morning Residual Effects

Crucially for titration decisions, next-morning sleepiness as measured by the Karolinska Sleepiness Scale was dose-dependent. The 10 mg group reported meaningfully higher morning sleepiness scores than the 5 mg group on nights 1 and 2. By week 4, the gap narrowed but did not disappear. [2] This gradient supports starting at 5 mg and waiting at least two to four weeks before escalating, so that tolerance to the sedative carry-over can be assessed.

Evidence From SUNRISE-2 on Long-Term Dose Use

SUNRISE-2 was a 12-month, randomized, placebo-controlled trial (N=949) that evaluated lemborexant 5 mg and 10 mg for insomnia disorder in adults aged 18 to 88. The primary results were published in Sleep and showed that both doses maintained statistically significant improvements in subjective sleep onset latency and WASO through 12 months without evidence of rebound insomnia upon discontinuation. [3]

Somnolence Rates by Dose

Treatment-emergent somnolence occurred in 10.1 percent of patients on 10 mg and 7.7 percent on 5 mg versus 1.3 percent on placebo. [3] The absolute difference between doses (about 2.4 percentage points) appears modest, but for a patient who needs to drive or operate machinery the morning after, it represents a clinically meaningful risk difference.

Discontinuation Due to Adverse Events

Adverse-event-driven discontinuation rates were 5.7 percent (10 mg), 3.2 percent (5 mg), and 2.0 percent (placebo) over 12 months. [3] The 5 mg cohort's discontinuation rate was closer to placebo, reinforcing the value of the lower dose for long-term tolerability.

Practical Slow-Titration Protocol for Clinical Use

The FDA label provides the regulatory floor; the protocol below builds on that framework for patients who are sensitivity-prone. This four-step approach is consistent with the prescribing information and the dose-response data from SUNRISE-1 and SUNRISE-2.

Step 1: Baseline Assessment (Before Night 1)

Confirm the following before writing the first prescription:

1. No narcolepsy diagnosis (absolute contraindication per FDA label [1])
2. Obtain medication list and screen for CYP3A4 inhibitors using the FDA drug interaction table
3. Document hepatic function if any concern about liver disease
4. Ask about prior sedative-hypnotic use and any history of complex sleep behaviors (sleep-walking, sleep-driving), which are a class-wide risk for DORAs [1]
5. Confirm the patient has a fixed wake time that allows at least 7 hours in bed after dosing

Step 2: Start at 5 mg, Weeks 1 to 4

Write the first prescription for lemborexant 5 mg. Instruct the patient to:

• Take the tablet within 30 minutes of getting into bed, not 30 minutes before getting into bed, to minimize the period of ambulatory risk while sedation begins
• Avoid alcohol on nights they take the medication; alcohol increases CNS depression and is not merely additive with lemborexant [1]
• Avoid driving the morning after if they feel residual sleepiness, regardless of how many hours they slept

Schedule a follow-up call or visit at two weeks to assess morning alertness, falls risk (especially in older adults), and subjective sleep quality.

Step 3: Decision Point at Week 4

At four weeks, the prescriber faces one of three scenarios:

• Adequate response with good morning alertness. Continue 5 mg. No escalation needed.
• Partial response with good morning alertness. Consider escalating to 10 mg. The FDA label permits this. [1]
• Any response with persistent next-morning somnolence. Do not escalate. Consider reducing the dose or switching to a non-pharmacologic approach. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment per the American Academy of Sleep Medicine. [4]

Step 4: Post-Escalation Monitoring at 10 mg

If the dose is increased to 10 mg, reassess within two weeks. SUNRISE-1 showed that next-morning somnolence is highest in the first two nights at the higher dose and then attenuates somewhat. [2] Patients should be warned explicitly about this early-dose period.

Titration in Special Populations

Older Adults (Age 65 and Older)

Adults 65 or older represented a distinct subgroup in both SUNRISE trials. The FDA label advises caution in this group and notes that falls and impaired driving performance the morning after are particular concerns. [1] A post-hoc analysis from SUNRISE-1 published in the Journal of Clinical Sleep Medicine found that lemborexant 5 mg reduced WASO in older adults without the next-morning balance impairment seen at 10 mg. [5] Starting at 5 mg and maintaining that dose unless there is a compelling reason to escalate is the prudent approach for any patient 65 or older.

Hepatic Impairment

Mild impairment (Child-Pugh A): start at 5 mg; escalation to 10 mg is possible with close monitoring. Moderate impairment (Child-Pugh B): 5 mg is the ceiling; do not escalate. Severe impairment (Child-Pugh C): lemborexant is not recommended. [1]

Drug Interactions Requiring Dose Adjustment

The table below summarizes the most common interaction scenarios.

| Co-medication | Effect on lemborexant | Recommended maximum dose | |---------------|----------------------|--------------------------| | Moderate CYP3A4 inhibitor (fluconazole, diltiazem) | Up to 2-fold increase in AUC | 5 mg [1] | | Strong CYP3A4 inhibitor (ketoconazole, clarithromycin) | Greater than 2-fold increase in AUC | Avoid lemborexant [1] | | Moderate CYP3A4 inducer (efavirenz) | Reduced exposure, possible loss of efficacy | Avoid combination [1] | | Strong CYP3A4 inducer (rifampin) | Substantially reduced exposure | Avoid combination [1] | | CNS depressants (opioids, benzodiazepines, alcohol) | Additive CNS depression | Use lowest effective dose; avoid alcohol [1] |

The FDA prescribing information should be consulted before combining lemborexant with any CYP3A4-modulating agent. [1]

Comparing Slow Titration to Abrupt Full-Dose Start

A retrospective analysis of real-world insomnia prescribing data published in the Journal of Managed Care and Specialty Pharmacy found that patients initiated on 10 mg of a DORA without a trial at the lower dose had a 1.6-times higher rate of early discontinuation due to adverse events compared with patients started at the lower dose. [6] While this analysis was not specific to lemborexant alone, the pharmacokinetic similarities within the DORA class make the finding directionally informative.

The American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacological treatment of chronic insomnia recommends using the lowest effective dose and reassessing periodically. [4] A slow upward titration embodies both principles.

When to Stop or Switch

Titration is not always forward. Signs that warrant reducing the dose or discontinuing lemborexant include:

• Next-morning somnolence persisting beyond four weeks at the current dose
• A fall, near-fall, or motor vehicle incident associated with residual sedation
• New diagnosis of moderate-to-severe sleep apnea (the FDA label notes that DORAs may worsen respiratory drive in susceptible patients [1])
• Onset of complex sleep behaviors (sleep-eating, sleep-driving), which require immediate discontinuation per the FDA's class-wide safety communication [7]
• Any new or worsening depression, as worsening of depression and suicidal ideation have been reported with sedative-hypnotics as a class [1]

Discontinuation of lemborexant does not require a taper. SUNRISE-2 showed no statistically significant rebound insomnia after abrupt cessation. [3] Still, clinicians may choose a brief step-down (10 mg to 5 mg for one week, then off) for patients who are anxious about stopping to provide psychological support.

How Lemborexant Titration Compares to Suvorexant

Suvorexant (Belsomra), the other FDA-approved DORA, has an approved range of 10 mg to 20 mg with 10 mg as the recommended starting dose. The FDA label for suvorexant notes that doses above 20 mg do not provide additional benefit and increase adverse events. [8] Lemborexant's lower approved starting dose and narrower range give clinicians a built-in "slow titration by design" framework that suvorexant does not offer.

A head-to-head pharmacodynamic comparison published in Clinical Pharmacology and Therapeutics found that lemborexant produced less next-morning driving impairment than suvorexant 20 mg at the lemborexant 10 mg dose, with lemborexant 5 mg showing essentially no driving-performance deficit versus placebo. [9] This data point supports keeping sensitive patients at 5 mg indefinitely if sleep quality is acceptable.

Monitoring Parameters During Titration

Clinicians should document the following at each visit or check-in during the titration period:

• Epworth Sleepiness Scale score (target <10 at follow-up)
• Patient-reported sleep onset latency and number of awakenings
• Morning alertness rating (1 to 10 scale)
• Any falls, near-falls, or complex sleep behaviors
• Changes to the medication list that could affect CYP3A4 activity

The Pittsburgh Sleep Quality Index (PSQI) is a validated eight-component self-report tool that takes about five minutes to complete and can track treatment response across titration steps. [10] A post-treatment PSQI global score below 5 corresponds to good sleep quality.